Fig. 3. Prognostic impact of genome-wide aberrant AS pattern among MDS patients.
Kaplan–Meier survival curves stratified by genome-wide aberrant AS pattern (with a cut-off point value at 2.45 of aberrant AS score) for overall survival (OS) (a) and time to leukemic change in total cohort of 176 MDS patients (b), OS in patients without any detectable mutation in genes related to splicing factors or epigenetic modifications (c), and OS in the validation cohort of 31 primary MDS patients (d). Note: SF(-)Epi(-) means neither splicing factor, nor epigenetic genes mutation